Synta Pharma (SNTA) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Roth Capital Positive on Synta (SNTA) Following Q3 Results; Focus Remains on Ganetespib Phase III GALAXY-2
November 6, 2014 2:09 PM ESTRoth Capital affirms Synta Pharma (Nasdaq: SNTA) at Buy with a price target of $27 following Q3 results reported earlier on the session.
Synta Pharma reported Q3 loss of $0.19 per share, $0.05 better than the analyst loss estimate of $0.24 per share.
Analyst Joseph Pantginis noted that Synta announced the... More
